Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
Venetoclax is a highly selective, potent, oral BCL-2 inhibitor, which induces apoptosis in multiple myeloma cells. It has shown encouraging clinical efficacy with acceptable safety and tolerability in a phase 1 trial. Median progression-free survival according to an independent review committee was 22.4 months.
